Placebo (Part A)

DRUG2 trials

Sponsors

Cytokinetics, Nanjing Immunophage Biotech Co., Ltd

Conditions

Amyotrophic Lateral SclerosisAtopic Dermatitis

Phase 1

A Study of Orally Administered IPG7236 in Healthy Adult Participants

TerminatedNCT05288543

Nanjing Immunophage Biotech Co., LtdAtopic Dermatitis

Start: 2022-04-07End: 2025-11-26Updated: 2025-12-22

Phase 2

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT01378676

CytokineticsAmyotrophic Lateral Sclerosis

Start: 2011-06-30End: 2012-03-31Updated: 2019-05-07